share_log

沃森生物(300142.SZ):目前正在基于9价HPV疫苗产品临床开发计划,保持与CDE密切沟通交流

Walvax Biotechnology (300142.SZ): Currently engaged in the clinical development plan for the 9-valent HPV vaccine product, maintaining close communication with the CDE.

Gelonghui Finance ·  Dec 26, 2024 21:05

On December 26, Gelonghui reported that Walvax Biotechnology (300142.SZ) recently stated in an investor relations activity that the work for its subsidiary in Shanghai, Ze Run, for the phase III clinical study of the 9-valent HPV vaccine is progressing continuously. Currently, the phase III clinical trial comparing the immunogenicity of this vaccine with similar vaccines is in the data statistics analysis and clinical research report writing phase. The company is actively maintaining close communication with CDE, striving to promote the clinical research of protective efficacy with the optimal strategy based on the clinical development plan for the 9-valent HPV vaccine product.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment